SavedAdd your journal

Journals / ANKEM Dergisi / 2018 / Cilt: 32 - Sayı: 3

Fosfomycin Susceptibility of ESBL Positive and Negative Escherichia coli and Klebsiella spp. Resistant to at Least One Carbapenem

Tuncer ÖZEKİNCİ
Nezahat AKPOLAT
Nida ÖZCAN
Selahattin ATMACA
Salim YAKUT
Kadri GÜL
Pages
87–93
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Fosfomycin can be used in resistant bacterial infections other than urinary tract with its high sensitivity in carbapenem-resistant E.coli and Klebsiella strains.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Extended spectrum beta-lactamase (ESBL) production and increased carbapenem resistance in Enterobacterales members have increased the interest in fosfomycin, an ancient antibiotic.
📊
Key Findings & Data:Carbapenem resistant E.coli and Klebsiella spp. isolated from various clinics and intensive care units, and outpatients during a one year period (January-December 2017) were included the study.
💡
Conclusion & Impact:Fosfomycin can be used in resistant bacterial infections other than urinary tract with its high sensitivity in carbapenem-resistant E.coli and Klebsiella strains.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Extended spectrum beta-lactamase (ESBL) production and increased carbapenem resistance in Enterobacterales members have increased the interest in fosfomycin, an ancient antibiotic. In the study, susceptibility of fosfomycin was investigated in ESBL positive and ESBL negative Escherichia coli and Klebsiella spp. strains resistant to at least one carbapenem (ertapenem, imipenem, meropenem). Carbapenem resistant E.coli and Klebsiella spp. isolated from various clinics and intensive care units, and outpatients during a one year period (January-December 2017) were included the study. Ot the 64 E.coli isolates, fosfomycin susceptibility of ESBL-negative strains (41/43 95.3 %) were higher than ESBL positives (17/21, 80.9 %). However, there was no statistically significant correlation between the presence of ESBL and the sensitivity of fosfomycin (p>0.05). In Klebsiella spp., fosfomycin susceptibility in ESBL negative isolates was 42/53 (79.2 %) with 16/29 (55.1 %) in ESBL positives. The relationship between ESBL and fosfomycin resistance in Klebsiella spp. was statistically significant (p0.05). Fosfomycin can be used in resistant bacterial infections other than urinary tract with its high sensitivity in carbapenem-resistant E.coli and Klebsiella strains.

🔖

Cite This Article

ÖZEKİNCİ, T., AKPOLAT, N., ÖZCAN, N., ATMACA, S., YAKUT, S., GÜL, K. (2022). Fosfomycin Susceptibility of ESBL Positive and Negative Escherichia coli and Klebsiella spp. Resistant to at Least One Carbapenem. ANKEM Dergisi, Cilt: 32 - Sayı: 3, 87–93. https://ajindex.com/articles/445572

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Afşar İ, Gönül B, Şener AG, Türker M. Escherichia coli’nin klinik izolatlarının fosfomisin trometamol ve diğer antibiyotiklere in-vitro duyarlılığı. ANKEM Derg. 2005;19(2):77-9.
  2. Aykut Arca E, Karabiber N. Kısa bildiri: Üriner sistem Escherichia coli izolatlarının fosfomisin trometamol ve çeşitli antibiyotiklere karşı duyarlılıklarının karşılaştırılması. Mikrobiyol Bul. 2007;41(1):115-9. Baylan O. Fosfomisin: dünü, bugünü ve geleceği. Mikrobiyol Bul. 2010;44(2):311-21.
  3. Bayram Y, Eren H, Berktaş M. İdrar örneklerinden izole edilen bakteriyel patojenlerin dağılımı ve GSBL pozitif ve negatif E.coli suşlarının fosfomisin ve diğer antimikrobiyallere duyarlılık paterni. ANKEM Derg. 2011;25(4):232-6. https://doi.org/10.5222/ankem.2011.232 Blondeau JM. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Drugs. 2004;64(6):611-28. https://doi.org/10.2165/00003495-200464060-00004
  4. Coşkun MV, Uyanık H, Ağan İ, Uslu H, Çelebi S. Hastanede yatan hastaların üriner sistem enfeksiyonlarından izole edilen genişlemiş spektrumlu beta-laktamaz üreten Klebsiella pneumoniae ve Escherichia coli suşlarının fosfomisin ve nitrofurantoine duyarlılıklarının araştırılması. ANKEM Derg. 2016;30(2):37-41. https://doi.org/10.5222/ankem.2016.037
  5. Çağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Özer S. CLSI ve EUCAST önerilerine göre genişlemiş spektrumlu beta-laktamaz üreten Escherichia coli idrar izolatlarında fosfomisin duyarlılığı. Mikrobiyol Bul. 2014;48(4):545-55. https://doi.org/10.5578/mb.8327 EUCAST (The European Committee on Antimicrobial Susceptibility Testing). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. http://www.eucast.org
  6. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extendedspectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43-50. https://doi.org/10.1016/S1473-3099(09)70325-1
  7. Fransen F, Hermans K, Melchers MJB, Lagarde CCM, Meletiadis J, Mouton JW. Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2017;72(12):3374-81. https://doi.org/10.1093/jac/dkx328
  8. Hoşbul T, Ozyurt M, Baylan O, et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul. 2009;43(4):645-9. Kart Yaşar